Abstract: Disclosed herein is a method of alleviating symptoms of ocular surface discomfort, the method comprising: topically applying a cold slurry adjacent to a corneal limbus of an eye of a patient, wherein the cold slurry comprises water and a freezing point depressant, wherein the topical application of the cold slurry is configured to cause a degree of numbing of a cornea of the eye for a period of time, and wherein an ocular sensation of the eye is restored following the period of time.

Abstract: Pharmaceutical formulations (nanococktails) include two or more nanoparticulate delivery vehicles each including an active agent. The nanococktails can be formulated at any ratio of active agents by changing the ratio of nanoparticulate delivery vehicles in the nanococktail. The nanoparticulate delivery vehicles can have matched surface potential to prevent aggregation. The nanoparticulate delivery vehicles of the combined formulation are designed to provide each active agent with desired, preferably overlapping therapeutic windows and a specifically selected pharmacokinetic and pharmacodynamic profile when the nanococktail is administered to a subject. Each of the nanoparticulate delivery vehicles can be designed to enhance solubility, duration of action, targeting, stability, and to program release while preventing degradation of an active agent and preventing side effects, toxicity, and tolerability issues in a subject.

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.

Abstract: Disclosed embodiments concern a composition and/or combination, and a method of administering the same as a feed, or to supplement the feed of, aquatic animals, particularly for aquaculture. Disclosed composition and/or combination embodiments may comprise glucan, silica, mineral clay, mannans, yucca, quillaja, a probiotic, and/or an adhesive agent. The adhesive agent may be selected particularly to facilitate administration to aquatic species. In certain embodiments the adhesive agent comprises an oil, such as soy oil, or a syrup, such as molasses, or combinations thereof. In some embodiments the composition and/or combination may further comprise polyphenol, an antimicrobial, and/or a vaccine. Also disclosed is a method for promoting growth and/or immune function in aquatic animals.

Abstract: A method of immunological evaluation includes cleaning a skin surface area of a patient. A controlled amount of heat is then applied to the skin surface area. The controlled amount of heat is removed after the skin surface area reaches a predetermined temperature. An amount of antigen is deposited onto the skin surface area and incubated for a predetermined amount of time on the skin surface area. The antigen is removed from the skin surface area and an immunological response at the skin surface area is evaluated. Apparatus for administering heat and memorializing the evaluation are also disclosed.

Abstract: The present disclosure relates to color-altering compositions. The compositions comprise a hair color-altering agent and at least one carboxylic acid. Certain compositions further comprise at least one amino acid or amino sulfonic acid, and/or a salt thereof selected from the group consisting of taurine, aspartic acid, cysteine, lysine, methionine, tyrosine, phenylalanine, carnitine, a salt thereof, and a mixture thereof. Also provided are kits and methods of using said color-altering compositions.

Abstract: An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.

Abstract: A medicament set adapted to regulate multiple receptors simultaneously in patients experiencing diabetic peripheral neuropathy pain, the medicament set comprising: at least three distinct and separate medicaments for treating diabetic peripheral neuropathy pain, the at least three medicaments being a first medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising polylactic glycolic acid (PLGA) micro-particles being loaded with a sodium channel blocker and local anesthetic drug, a second medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with a sodium channel blocker and anti-convulsant drug, and a third medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using a

Abstract: Compositions for the treatment of some orphan diseases and oral mucosal ulcers, many with similarities in terms of their anti-inflammatory and anti-oxidative activities, but also multiple differences in their observed abilities that can be combined to challenge the current, underlying pathophysiology. The orphan diseases of interest are Dupuytren's Contracture, Peyronie's Disease, Scleroderma, Raynaud's (or Renaud's) Phenomenon, chemotherapy/radiation induced oral mucosal ulceration, and aphthous ulcers; and more frequent skin issues of skin damage from cuts, abrasions, and burns; aging skin changes, and toe nail fungus. These can be treated with the disclosed compositions with the proper combination and alteration of ingredients inclusive of alpha-pinene, an aloe vera preparation, and a shea butter preparation. A process for preparation of such ingredients in a water-in-oil emulsion is described herein.

Abstract: The present invention relates to a hydrogel formulation for delivering probiotics including a hydrogel, probiotics and zwitterionic buffer as an active ingredient, a composition for delivering probiotics comprising the same and a method of preparing the same, which adjust and maintain the internal pH of the hydrogel even in the gastric juice environment, thereby increasing the survival rate of the probiotics in the gastric juice and improving the delivery rate to the large intestine, by further adding zwitterionic buffer capable of maintaining pH to the hydrogel encapsulated with probiotics.

Abstract: A nutritional supplement containing fish oil and selenium has been identified that enhances immunotherapy of tumors, particularly in regard to reducing PDL-1 expression. A formulation for such a supplement that is both well tolerated and palatable is also provided.

Abstract: This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions for treatment of opioid dependence, pain or depression, including an aqueous suspension of crystalline 3-acyl-buprenoprhine, or a pharmaceutically acceptable salt thereof, wherein the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. This disclosure also includes 3-acyl-buprenoprhine or a pharmaceutically acceptable salt thereof prepared in a controlled release matrix, including poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein and a combination of two or more thereof.

Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.

Abstract: Compositions and kits for oral administration of a phosphodiesterase-4 (PDE4) inhibitor and one or more additional active agents that reduces or eliminates a side effect associated with the PDE4 inhibitor are provided. Also provided are methods for use of these compositions and kits for treating conditions treatable with a PDE4 inhibitor therapy and for increasing patient compliance with treatment with PDE4 inhibitors.

Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.

Abstract: The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 ?m.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: Provided herein are compositions comprising ixabepilone, or a pharmaceutically acceptable salt thereof, and a copolymer represented by formula I: Also provided are methods of treating cancer using the compositions described herein, and methods of preparing the compositions.

Abstract: A gas permeable layer capable of supplying hydrogen includes a thin layer, encapsulating a hydrogen production formula. An outer side of the thin layer is airtight. An inner side is air-permeable. An inner side surface has a plurality of small holes. The thin layer can be a single layer or a composite layer. The hydrogen production formula does not dissipate. The hydrogen production formula absorbs moisture in the air or liquid water, thereby generating hydrogen. The hydrogen is released onto the skin and into the human body through the small holes. The hydrogen production formula includes metal peroxides, metal hydroxides, or metal hydrides and aluminum powder, or microsilica. The gas permeable layer can be used in sanitary products including eye masks, mouth masks, face masks, cosmetic facial masks, bras, pasties, nursing pads, sanitary napkins (towels), diapers, panty liners, wound dressing, woundplasts, bandage gauze, decubitus pads.